Swine Neonatal Care Technician

eGenesis appoints Glenn S. Vraniak as Chief Financial Officer and Jennifer Bergheiser as Chief Commercial Officer. Provided by Business Wire Jun 22, 2026, 5:00:00 AM Leadership additions support company's advancement through the next phase of growth eGenesis, a biotechnology company developing human-compatible engineered organs for transplantation, today announced the appointments of Glenn S. Vraniak as Chief Financial Officer and Jennifer Bergheiser as Chief Commercial Officer. Glenn S. Vraniak, Chief Financial Officer, eGenesis The appointments come as eGenesis advances in clinical studies across multiple programs, including EGEN-2784 for kidney failure and a program for acute-on-chronic liver failure, positioning the company for its next phase of growth. "eGenesis is entering a pivotal stage in our evolution as we prepare to advance our programs through clinical development and lay the foundation for future commercialization," said Mike Curtis, Ph.D., Chief Executive Officer, eGenesis. "Glenn brings deep expertise and proven leadership across finance, capital formation, and business development and we are thrilled to have him join the team to help drive the next phase of growth for the company." Mr. Vraniak brings more than two decades of executive leadership experience across biotechnology, medical technology and specialty pharmaceuticals, with a track record of leading capital raising initiatives, IPOs, strategic transactions and company-building initiatives. Most recently, he served as Chief Financial Officer of Inversago Pharma, where he helped lead the company's growth strategy, financing activities and eventual acquisition by Novo Nordisk in a transaction valued at approximately $1.1 billion. Prior to Inversago, he served as CFO of Evaxion Biotech, Valeo Detection Systems and electroCore. He also served on the Board of Directors of Apollomics Inc, where he chaired the Audit Committee. Throughout his career, Mr. Vraniak has helped raise hundreds of millions of dollars in private and public capital, led IPO processes and supported strategic transactions across both public and private companies. Most recently, at Inversago, he completed a $70 million Series C financing, prepared the company for a potential IPO and played a key role in negotiating its acquisition by Novo Nordisk. "eGenesis has built one of the most innovative platforms in biotechnology and is addressing one of the largest unmet needs in medicine," said Vraniak. "The opportunity to revolutionize the treatment of organ failure and potentially save countless lives is incredibly compelling. I look forward to working alongside this talented team as we advance our clinical programs, strengthen our operational capabilities and position the company for long-term success." Jennifer Bergheiser has been promoted to Chief Commercial Officer after serving as Chief Business Officer at the company since 2022. Ms. Bergheiser brings more than 25 years of experience across biopharmaceuticals, biotechnology, private equity and strategy consulting. Her career has included leadership roles spanning product strategy, commercialization planning, business development and market access. She has extensive experience supporting new product planning and commercialization efforts across multiple therapeutic areas and new modalities, including early brand and commercial strategy for blockbuster biologic therapies such as Stelara(R). In her new role, Ms. Bergheiser will lead product and market development activities for eGenesis' lead kidney program, EGEN-2784, as well as the company's broader pipeline. She will oversee product management, market access, government affairs, patient advocacy and channel strategy as eGenesis prepares for future commercialization and the transformation of the treatment of organ failure enabled by expanded organ supply. "Jen has a proven track record of building and scaling high-performing teams at eGenesis," said Curtis. "She has led key functions across G&A while driving our new product planning efforts over the past several years. We look forward to her continued leadership as we begin laying the foundation for commercialization." "The shortage of organs for transplant is a public health crisis, exacting a staggering toll on patients, families, clinicians and healthcare systems," said Bergheiser. "The opportunity to lead eGenesis' efforts in preparing the market, and our game-changing product portfolio, for commercialization is unmatched. I look forward to partnering with stakeholders across the healthcare landscape to help define a new category of medicine and enable access to a novel and life-saving treatment option for people whose lives have been put on hold by organ failure." About eGenesis eGenesis is a clinical-stage biotechnology company developing human-compatible engineered organs to address the severe global organ shortage. The Company's proprietary genome engineering platform enables extensive, multiplex gene edits to remove key biological barriers, add protective human transgenes, and inactivate endogenous retroviruses. EGEN-2784, a genetically engineered, porcine-derived kidney product, is the Company's lead program for patients with kidney failure. The Company has received FDA clearance to conduct clinical studies across its kidney and liver programs. eGenesis is headquartered in Cambridge, MA. For more information, visit www.egenesisbio.com. The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar. Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees. Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

eGenesis to participate at BIO International Convention 2026 panel on the future of xenotransplantation. June 18, 2026 CEO & President Mike Curtis joins industry leaders to discuss the clinical progress and potential of xenotransplantation to address the global organ shortage. CAMBRIDGE, Mass. - (BUSINESS WIRE)-eGenesis, a biotechnology company developing human-compatible organs for transplantation, today announced that Michael Curtis, Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the BIO International Convention 2026 titled "Xenotransplantation Enters the Clinic: The Next Frontier in Solving Organ Shortage." As xenotransplantation advances from scientific possibility to clinical reality, the panel will examine the latest progress in gene-edited organ transplantation, advances in genome engineering, and the path toward broader clinical adoption. Session Details Xenotransplantation Enters the Clinic: The Next Frontier in Solving Organ Shortage Date: Monday, June 22, 2026 Time: 3:00 p.m. - 4:00 p.m. PT Location: Room 24BC, San Diego Convention Center Panelists: * Jonathan Grinstein, Ph.D., North American Editor, Inside Precision Medicine (Moderator) * Cameron Lillie-Liberto, Kidney Disease Patient Advocate * Jesse Roach, M.D., Senior Vice President, Government Relations, National Kidney Foundation * Xiaoxi (Sofie) Wei, Ph.D., CEO & Co-Founder, X-Therma * David Yang, Partner, Lux Capital "Xenotransplantation is at a pivotal moment as decades of innovation in genome engineering and transplantation science have enabled advancement to clinical studies," said Curtis. "I look forward to joining this distinguished group of experts to discuss the progress being made and the potential for xenotransplantation to expand access to lifesaving organ transplantation for patients around the world." Panelists will discuss the scientific, clinical, regulatory, patient, and investment perspectives shaping the future of xenotransplantation, including how advances in gene editing are addressing immune rejection and viral risk, the design of first-in-human studies, and what it will take to scale xenotransplantation into a viable treatment option for patients with organ failure. More than 800,000 Americans and millions worldwide suffer from end stage kidney disease or ESKD. While organ transplantation remains the gold standard for improving survival and quality of life among those living with kidney failure, due to the shortage of organs, only 27,573 kidney transplants were performed in 2025. For those unable to receive a transplant, dialysis remains the only option. The five-year mortality rate associated with dialysis is approximately 60%, higher than the most common cancers. Genetically engineered porcine-derived kidneys offer a promising solution to this crisis. About eGenesis eGenesis is a clinical-stage biotechnology company developing human-compatible engineered organs to address the severe global organ shortage. The Company's proprietary genome engineering platform enables extensive, multiplex gene edits to remove key biological barriers, add protective human transgenes, and inactivate endogenous retroviruses. EGEN-2784, a genetically engineered porcine kidney, is the Company's lead program and is currently being evaluated in a multi-patient Expanded Access study at MGH. The company is also advancing programs focused on acute liver failure and heart failure. eGenesis is headquartered in Cambridge, MA. For more information, visit www.egenesisbio.com. Media Contact